Plasma membrane anionic phospholipids and cell-surface glycosaminoglycans

Plasma membrane anionic phospholipids and cell-surface glycosaminoglycans (GAGs) constitute a distinct class of therapeutic targets defined by their concentrated negative charge on the extracellular surface. In normal physiological conditions, anionic phospholipids like phosphatidylserine (PS) are actively maintained in the inner leaflet of the plasma membrane by flippases, while GAGs like heparan sulfate are regulated components of the glycocalyx (Source: PubMed, PMID: 16126121). However, in pathological states such as cancer or viral infection, the loss of membrane asymmetry leads to the externalization of PS, and GAG expression is often upregulated to facilitate signaling and adhesion (Source: NIH, National Cancer Institute). Therapeutic agents such as the oncolytic peptide LTX-315 and the monoclonal antibody Bavituximab (which targets PS via beta-2-glycoprotein I) leverage these anionic signatures to achieve tumor-selective activity (Source: PubChem, CID 11552600). These interactions can lead to direct membrane disruption, inhibition of viral entry, or the reprogramming of the immunosuppressive tumor microenvironment into a pro-inflammatory state (Source: Journal of Clinical Oncology, DOI: 10.1200/JCO.2013.52.0965). Despite their promise, therapeutic challenges include potential off-target effects on healthy cells with high GAG density and the inherent pharmacokinetic difficulties of targeting broadly distributed surface molecules.

Other names

Anionic cell surface componentsNegatively charged membrane lipids and glycansTumor-exposed anionic phospholipidsAnionic membrane surface

Binding to negatively charged cell surface components to induce membrane lysis, inhibit viral entry, or promote immune-mediated clearance.